gene - International Biopharmaceutical Industry

news

Scientists home in on cause of Duchenne gene therapy side effect

Duchenne muscular dystrophy, a degenerative disease mostly affecting young boys, is one of the top targets for gene therapy developers. Recently, however, the pace of...

30 May 2022 news Duchenne | dystrophy

Continue Reading →

news

Scientists home in on cause of Duchenne gene therapy side effect

Duchenne muscular dystrophy, a degenerative disease mostly affecting young boys, is one of the top targets for gene therapy developers. Recently, however, the pace of...

22 May 2022 news Disease | Duchenne

Continue Reading →

news

Undeterred by gene therapy’s struggles, a startup launches into a downturn

Gene therapy companies have been especially vulnerable to a public market downturn that’s shaken the biotech sector. But the difficult environment hasn’t stopped vent...

28 April 2022 news Apertura | gene

Continue Reading →

news

Solid Bio joins slate of biotech layoffs, shedding 35% of its workforce

Dive Brief: Gene therapy developer Solid Biosciences is laying off 35% of its employees, announcing Wednesday a plan to extend its current funds for another two ye...

28 April 2022 news BIO | Biotech

Continue Reading →

news

Regeneron, in search of an eye gene therapy, turns to a young biotech

Dive Brief: Through a deal announced Wednesday, a German-based biotechnology company has agreed to help Regeneron develop a gene therapy for an inherited retinal d...

11 April 2022 news biotechnology | eye

Continue Reading →

news

Orchard turns to layoffs in cutting gene therapy research

Dive Brief: Orchard Therapeutics, a London- and Boston-based developer of gene therapies, plans to lay off 30% of its workforce, or about 65 employees, as it moves...

1 April 2022 news Boston | gene

Continue Reading →

news

As biotech retreats, gene therapy companies retrench and redraw plans

Bluebird bio has spent the better part of two decades developing gene therapies for rare diseases. This summer, after years of clinical trials, setbacks and delays, t...

25 March 2022 news Biotech | companies

Continue Reading →

news

Spark CEO Marrazzo, who led company to historic gene therapy approval, to step down

Jeffrey Marrazzo, CEO of gene therapy developer Spark Therapeutics, will step down as head of the company he co-founded almost nine years ago, steered to a historic F...

24 February 2022 news approval | CEO

Continue Reading →

news

In England, Orchard secures rare agreement on gene therapy coverage

Dive Brief: The National Health Service in England and Wales will cover treatment with an exceptionally high-priced gene therapy for a rare and fatal genetic disea...

6 February 2022 news coverage | gene

Continue Reading →

news

Gene editing startup Metagenomi raises $175M to advance research pipeline

Metagenomi, a biotech startup that three months ago struck a research alliance with Moderna, has raised $175 million to expand and build on its early research explori...

27 January 2022 news Biotech | editing

Continue Reading →